Clinical Trial

APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
An open, multicenter, dose-exploring Phase I trial include Part A and Part B to evaluate the safety, tolerability and efficacy of APG-2449.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-11-12; most recent amendment 2026-07-20.
Status change: Not Yet Recruiting → Recruiting 2025-02-24
Trial Details
NCT Number NCT06687070
Lead Sponsor Ascentage Pharma Group Inc.
Conditions Platinum-resistant Recurrent Ovarian Cancer, Advanced Solid Tumor
Enrollment 90 participants
Start Date 2024-12-17
Primary Completion 2027-05 (estimated)
Study Completion 2028-05 (estimated)
Updated on ClinicalTrials.gov 2026-07-21